The Allergan logo is seen in this photo illustration November 23, 2015. REUTERS/Thomas White/Illustration/File Photo
(Reuters) – Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer’s disease therapy Namenda, resolving the litigation that was set to face trial this month.
Under the agreement, the drugmaker’s Forest units will pay $750 million to the plaintiff, which will be recorded as a charge in its third-quarter results.
The company said the settlement makes no admission of wrongdoing on its part.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur